Research And Application Of Chemotherapy Combined With DC-CIK Cells In Advanced Non-small Cell Lung Cancer

Objective: By comparing the clinical effects of chemotherapy combined with DC-CIK and chemotherapy alone in advanced non-small cell lung cancer,the changes in the number of T lymphocyte subsets(CD3+,CD4+,CD8+,CD4+/CD8+)before and after treatment,the changes in the data of quality of life scoring scale,and the adverse reactions during reinfusion were observed to judge the clinical effects.Methods:Twenty patients with stage IIIb-IV non-small cell lung cancer admitted to the Department of Oncology,Inner Mongolia Autonomous Region People's Hospital from September 2016 to October 2018 were selected and divided into experimental group and control group,with 10 patients in each group.The control group received paclitaxel combined with cisplatin(TP)chemotherapy.The test group was given paclitaxel and cisplatin combined with DC-CIK.The specific plan was: subcutaneous DCs cells were given during chemotherapy d7,DC-CIK was infused intravenously during chemotherapy d10-d14.T lymphocyte subsets(CD3+,CD4+,CD8+,CD4+/CD8+)before and after treatment were detected by flow cytometry.EORTC-QLQ scale was used to evaluate the quality of life of the test group before and after treatment,and the occurrence of adverse reactions after reinfusion was recorded.RECIST1.1 standard was used to evaluate the clinical efficacy of the two groups of patients.All data were processed by SPSS 20.0 statistical software,and the measurement data were expressed as "`x±s".the comparison between the two groups of patients was conducted by test(normal distribution),with p<0.05 as the difference having statistical significance.Results:(1)the changes of T lymphocyte subsets before and after treatment in the test group and the control group are as follows: the number of CD3+,CD4+,CD8+T lymphocytes in the test group after treatment is significantly higher than that before treatment,P<0.05,the difference is statistically significant;After treatment,the number of CD3+ and CD4+Tlymphocytes in the control group increased and the number of CD8+ T lymphocytes decreased,but there was no statistical difference(P ? 0.05).After treatment,the number of T lymphocyte subsets(CD3+,CD4+,CD8+)in the experimental group was compared with that in the control group.The number of CD3+,CD4+,CD8+T lymphocytes in the experimental group was significantly higher than that in the control group after treatment,P<0.05,and the difference was statistically significant.(2)After EORTC-QLQ evaluation of the quality of life of the experimental group before and after treatment,it can be seen that the role function,cognitive function,social function,shortness of breath,insomnia,diarrhea,nausea / vomiting,loss of appetite and other problems of the experimental group have been improved after treatment,and the difference is statistically significant;(3)Three patients in the test group developed fever after treatment,up to 39 degrees Celsius,which was caused by allergy.(4)DCR = 50% in the test group and 40% in the control group,P?0.05,with no significant difference.Conclusion:After DC-CIK cells were reinfusion in the test group,the comparison of T lymphocyte numbers was as follows: CD3+,CD4+,CD8+T lymphocyte numbers were significantly higher than before treatment,suggesting that the immune function of patients was significantly improved,which could improve the immune activity and reduce the immunosuppression for patients with advanced non-small cell lung cancer.The test group can obviously improve the quality of life of patients with advanced non-small cell lung cancer after reinfusion of DC-CIK.Meanwhile,adverse reactions during reinfusion are relatively mild,so chemotherapy combined with DC-IK can provide a new approach for the treatment of advanced non-small cell lung cancer patients.